Cobiz Investment Management buys $7,949,569 stake in Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : Cobiz Investment Management scooped up 6,139 additional shares in Johnson & Johnson during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 11, 2016. The investment management firm now holds a total of 66,357 shares of Johnson & Johnson which is valued at $7,949,569.Johnson & Johnson makes up approximately 1.92% of Cobiz Investment Management’s portfolio.

Other Hedge Funds, Including , Thompson Rubinstein Investment Management Inc Or reduced its stake in JNJ by selling 1,245 shares or 1.63% in the most recent quarter. The Hedge Fund company now holds 75,284 shares of JNJ which is valued at $9,019,023. Johnson & Johnson makes up approx 3.44% of Thompson Rubinstein Investment Management Inc Or’s portfolio.Central Bank Trust Co boosted its stake in JNJ in the latest quarter, The investment management firm added 114 additional shares and now holds a total of 16,842 shares of Johnson & Johnson which is valued at $2,008,240. Johnson & Johnson makes up approx 0.57% of Central Bank Trust Co’s portfolio.North Star Asset Management Inc reduced its stake in JNJ by selling 3,119 shares or 7.13% in the most recent quarter. The Hedge Fund company now holds 40,604 shares of JNJ which is valued at $4,839,185. Johnson & Johnson makes up approx 0.54% of North Star Asset Management Inc’s portfolio.Lau Associates reduced its stake in JNJ by selling 1,175 shares or 2.77% in the most recent quarter. The Hedge Fund company now holds 41,277 shares of JNJ which is valued at $4,919,393. Johnson & Johnson makes up approx 5.02% of Lau Associates’s portfolio.

Johnson & Johnson closed down -2.16 points or -1.80% at $117.64 with 63,94,159 shares getting traded on Tuesday. Post opening the session at $119.41, the shares hit an intraday low of $117.06 and an intraday high of $119.63 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Johnson & Johnson reported $1.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.68. The company had revenue of $18482.00 million for the quarter, compared to analysts expectations of $17985.80 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS.

Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by UBS on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 137 from a previous price target of $126 .Company shares were Reiterated by RBC Capital Mkts on Jul 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 133 from a previous price target of $125 .

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Leave a Reply

Johnson & Johnson - Is it time to Sell?

Top Brokerage Firms are advising their investors on Johnson & Johnson. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.